Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers

RF was positive in 24 (60%) and anti-CCP was positive in 26 (65%) patients among the 40 patients with RA.Conclusion: Anti-CCP may be helpful in the differential diagnosis between RA and chronic HBV infection or inactive HBV carrier status

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: Rheumatoid factor (RF) positivity that may occur in a number of patients with hepatitis B (HBV) infection poses challenges in terms of differential diagnosis with rheumatoid arthritis (RA).

📊

Key Findings & Data:This study aimed to assess anti-CCP and RF positivity among patients with hepatitis B and rheumatoid arthritis.Material and Methods: Anti-CCP and RF seropositivity was assessed in 61 patients with HBV infection (32 patients with chronic hepatitis, 29 patients with inactive HBV carrier status) and 40 patients with RA as the control group.

💡

Conclusion & Impact:RF was positive in 24 (60%) and anti-CCP was positive in 26 (65%) patients among the 40 patients with RA.Conclusion: Anti-CCP may be helpful in the differential diagnosis between RA and chronic HBV infection or inactive HBV carrier status

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: Rheumatoid factor (RF) positivity that may occur in a number of patients with hepatitis B (HBV) infection poses challenges in terms of differential diagnosis with rheumatoid arthritis (RA). On the other hand, antibodies to cyclic citrullinated peptide (anti-CCP) may prove to be an important marker for differential diagnosis of the two conditions. This study aimed to assess anti-CCP and RF positivity among patients with hepatitis B and rheumatoid arthritis.Material and Methods: Anti-CCP and RF seropositivity was assessed in 61 patients with HBV infection (32 patients with chronic hepatitis, 29 patients with inactive HBV carrier status) and 40 patients with RA as the control group. Results: RF positivity was found in 18.7% and 34.4% of the patients with chronic hepatitis B and inactive HBV carrier status, respectively. On the other hand, only one patient with chronic HBV had low positive anti-CCP. RF was positive in 24 (60%) and anti-CCP was positive in 26 (65%) patients among the 40 patients with RA.Conclusion: Anti-CCP may be helpful in the differential diagnosis between RA and chronic HBV infection or inactive HBV carrier status

🔖

Cite This Article

DALKILIÇ, E., ÖKSÜZ, M. F., NİZAMOĞLU, A., TUFAN, A. N., ÖZBEK, A., DOLARSLAN, M. E., COŞKUN, B. N., PEHLİVAN, Y. (2022). Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers. European Journal of Rheumatology, Cilt: 2 - Sayı: 2, 62–65. https://ajindex.com/articles/511819

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Peng YC, Hsieh SC, Yang DY, Tung CF, Hu WH, Huang WN, et al. Expression and clinical significance of an-tinuclear antibody in hepatitis C virus infection. J Clin Gastroenterol 2001; 33: 402-6. [CrossRef] 2. Watanabe K, Ohkubo Y, Funahashi Y, Nishimaki T, Moritoh T, Kasukawa R, et al. An investigation on rheumatoid factor of different immuno-globulin classes in hepatitis B virus carriers. Clin Rheumatol 1991; 10: 31-7. [CrossRef] 3. Csepregi A, Nemesanszky E, Rojkovich B, Poor G. Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link. J Rheumatol 2001; 28: 474-7. 4. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62; 870-4. [CrossRef] 5. Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007; 26: 17-23. [CrossRef] 6. Vander Cruyssen B, Peene I, Cantaert T, Hoffman IE, De Rycke L, Veys EM, et al. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Au-toimmun Rev 2005; 4: 468-74. [CrossRef] 7. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies pre-cede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6. [CrossRef] 8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheu-matism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. [CrossRef] 9. Aletaha D, Neogi T, Silman AJ, Funovits J, Fel-son DT, Bingham CO 3rd, et al. 2010 rheuma-toid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8. [CrossRef] 10. Liu FC, Chao YC, Hou TY, Chen HC, Shyu RY, Hsieh TY, et al. Usefulness of anti-CCP antibod-ies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia. Clin Rheumatol 2008; 27: 463-7. [CrossRef] 11. Wener MH, Hutchinson K, Morishima C, Gretch DR Absence of antibodies to cyclic citrullinat-ed peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004; 50: 2305-8. [CrossRef] 12. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP anti